tigecycline [1, 3, 4] . Although all these studies are from retrospective clinical evaluations of data from previous pharmacokinetic studies, the information aligns closely with mechanistic in vitro studies and has strong biological plausibility [4] . In vitro data describing antibiotic exposures that can suppress emergence of resistance also are available [7] , although these have not been systematically studied clinically. Furthermore, data associating excessive drug exposures with drug-related toxicity is also accessible [8] . To this end, using an approach to antibiotic dosing that ensures achievement of these drug exposures, often measured as unbound drug, associated with improved patient outcomes has been recommended in leading international clinical practice guidelines of the management of adults with hospital-acquired and ventilator-associated pneumonia [9, 10] .
A prominent challenge for achieving target antibiotic exposures, is antibiotic pharmacokinetic variability, which causes optimal doses to be difficult to predict. Whilst much pharmacokinetic variability is driven by dramatic variations in drug clearance from changes in predominantly renal function, from augmented renal clearance (a supranormal creatinine clearance driven by systemic inflammatory response to infection) to severe acute kidney injury. Changes in the volume of distribution of hydrophilic antibiotics like beta-lactams, aminoglycosides and glycopeptides can also affect the magnitude of dose required. Finally, use of extracorporeal therapies including renal replacement therapy and extracorporeal membrane oxygenation can have difficult to predict effects on antibiotic dosing requirements [4] .
A further challenge for ensuring optimal antibiotic exposures is that these are contingent on the susceptibility of the pathogen, which is described as the minimum inhibitory concentration (MIC) of the bacteria to the selected antibiotic. Epidemiological studies have shown that critically ill patients very commonly are infected by less susceptible pathogens [11] . In this scenario, the MIC, or denominator of the PK/PD index is higher, requiring a higher PK exposure (numerator) to ensure the minimum PK/PD index is achieved. That is, a higher dose is required to treat for less susceptible pathogens. It should be noted that use of MICs to guide antibiotic doses in individual patients is considered problematic because of the delay in reporting and variability in laboratory testing results. To account for these challenges, Mouton et al. have recommended that where the MIC is below the susceptibility breakpoint, that the breakpoint value should be used as the denominator in the PK/PD index. a b Fig. 1 a An optimal process for dose personalisation using rapid diagnostics and antibiotic susceptibility testing, dosing software and therapeutic drug monitoring (TDM); b a process for dose personalisation in resource poor settings However, where the MIC exceeds breakpoint, a value two dilutions higher than that reported, is recommended (i.e., reported MIC 4 mg/L where breakpoint is 2 mg/L, then use 16 mg/L) [12] .
Knowledge of PK/PD (drug exposure relative to pathogen susceptibility) is vital to personalising antibiotic dosing, but obtaining this data in a timely manner is essential given the high level of sickness of severity of critically ill patients. To this end, advancing beyond traditional antibiotic susceptibility testing methods is required as these may take 48-96 h to provide definitive characterisation of a cultured organism and application of microbiological rapid diagnostics (e.g., multiplex PCR testing and rapid whole genome sequencing) is needed.
Achieving effective antibiotic exposures by assessing a patient's needs at the bedside does not result in consistent achievement of therapeutic concentrations [2] . As such, various alternative approaches to dosing should be considered. Firstly, through use of unit-level interventions (e.g., prolonged infusions of beta-lactams [5] ). Secondly, use of nomograms that recommend doses using patient renal function or body weight [13] . Thirdly, dosing software that applies knowledge of the effect of patient characteristics on dosing requirements [6] . Fourthly, therapeutic drug monitoring (TDM) to measure drug exposures and then adjust dosing, as needed, to achieve therapeutic exposures [14] . Finally, combining TDM with dosing software and apply Bayesian forecasting for more sophisticated dose adjustment [15] . Use of any of the final three dosing interventions remains uncommon, yet represents the approaches most likely to ensure personalised doses that most consistently achieve therapeutic exposures.
Application of PK/PD to personalise antibiotic dosing can be performed in any patient regardless of the resources available to the hospital or clinician [1] . More resources, of course, will increase the sophistication of the approach to dose optimisation. In the future, it is likely that a highly sophisticated approach to accurate dosing could be applied (Fig. 1) . This approach would use effective empiric antibiotic doses using dosing software, supplemented by rapid diagnostics and susceptibility testing to guide optimal antibiotic selection for the causative pathogen. Empiric dosing of directed antibiotic therapy would again use dosing software, with subsequent dosing optimised using an iterative process of TDM combined with Bayesian forecasting within dosing software [4] . Targets could be set at maximal bacterial killing or suppression of resistance, depending on the probability of drug toxicity that would increase with higher drug exposures.
In conclusion, antibiotic dosing in critically ill patients is highly challenging, but should be considered a key intervention to further improve infection-related outcomes. To this end, a more personalised approach to drug dosing, which understands pharmacokinetics in the individual patient and pathogen susceptibility (MIC), is required. Using dosing interventions, including application of dosing software and TDM, it is possible to ensure more patients achieve target drug exposures. To date, this has not been widely investigated, and trials to quantify to what extent this intervention can increase clinical cure and patient survival, or even reduce emergence of antibiotic resistance, are eagerly anticipated.
